TLDR
-
Scilex shares jumped 10% after iHolding proposed a $100M stock deal.
-
iHolding plans to buy SCLX shares at $15 each under the term sheet.
-
The funding could support Scilex’s growth, products, and partnerships.
-
The deal still needs due diligence, approvals, and final agreements.
-
Scilex framed the deal as support for its non-opioid pain platform.
Scilex Holding Company (SCLX) shares rose sharply after the company announced a proposed $100 million common stock investment from iHolding Group LLP. SCLX gained 10.00% to $8.59 after briefly moving above $10 in early trading. The stock later pulled back, yet it recovered steadily and traded near session highs by late morning.
Scilex Stock Rises After Proposed Investment
Scilex said it signed a binding term sheet with iHolding Group LLP, a private investment group based in Almaty, Kazakhstan. The agreement outlines a planned purchase of newly issued Scilex common shares. The proposed investment would total $100 million, subject to further approvals and final agreements.
The company expects iHolding to buy shares at $15.00 each. That price would represent about 6.67 million new shares. The proposed deal values the stock above its late-morning trading level.
The announcement gave SCLX fresh momentum during the session. Shares spiked early, then gave back part of the move. However, the stock regained strength as traders reacted to the financing plan.
iHolding Deal Targets Scilex Growth Plans
Scilex plans to use the proposed investment to support its strategic growth. The company listed product development, commercialization, acquisitions, and partnerships among its expected uses. It also plans to support working capital, operations, intellectual property and broader corporate needs.
Scilex operates in non-opioid pain management and related healthcare markets. The company focuses on products for acute pain, chronic pain, neurodegenerative disease, and cardiometabolic disease. As a result, the proposed funding could support both commercial operations and pipeline work.
The deal still requires several steps before completion. The parties must finish due diligence and negotiate definitive agreements. They also need board approvals, stockholder approval, and any required regulatory clearances.
Kazakhstan-Linked Capital Expands Healthcare Push
iHolding described the proposed Scilex investment as part of a wider healthcare and biotechnology strategy. The group focuses on healthcare, technology, and cross-border strategic investments. It operates as a private investment vehicle in the Medeu District of Almaty.
The proposed deal also fits Kazakhstan’s growing interest in healthcare and biotechnology development. iHolding aims to support pharmaceutical manufacturing, research, biotechnology innovation, and international healthcare distribution. Therefore, the Scilex transaction could connect U.S. biotech activity with Central Asian healthcare ambitions.
Scilex framed the proposed investment as a strategic growth opportunity. The company also noted that the transaction remains conditional and incomplete. Still, the announcement lifted SCLX stock as the market reacted to the size and proposed pricing of the deal.
4th of July Flash Sale – 50% OFF!
Celebrate Independence Day by investing in your future. For a limited time, get 50% OFF a Knockout Stocks membership and unlock our latest high-conviction stock picks, powered by our proprietary KO Score algorithm.
You'll also get access to our long-term investment ideas and shorter-term trade opportunities, helping you identify potential opportunities before the crowd.
Sign up to Knockout Stocks today and get 50% OFF to unlock the full list of premium stock picks.
Use coupon code SPECIAL50 for your exclusive discount.
Offer ends soon. Don't miss out!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
